Human decidua-derived mesenchymal stromal cells differentiate into hepatic-like cells and form functional three-dimensional structures

Bornstein, Rafael; Macías, María Isabel; Torre, Paz de la; Grande, Jesús; Flores, Ana I.

doi:10.3109/14653249.2012.706706

Cited by 22 publications

(14 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1). They have been obtained from MSCs which were originated from BM [30][31][32][33], AT [34][35][36], UC and/or WJ [37][38][39], and decidua [40] samples. An increased efficiency of this process was achieved in P3-P5 human MSCs by different research groups who have applied defined sequential protocols [30,32,38,39], as reviewed by Volarevic et al [41].…”

Section: Plasticity: Mscs-derived Hepatocyte-like Cellsmentioning

confidence: 99%

“…A shortage and/or improvement in this differentiation process can be achieved by culturing cells in hypoxic conditions [39] or on extracellular matrix [32]. Differentiated cells were found to: express hepatocyte markers (such as AAT, AFP, albumin, CK18, CX32, CYP1A1, CYP3A4, CYP7A1, G6P, HepPar, HGFR and/or HNF-4a) [35,38,39], store glycogen and/or uptake/secrete indocyanine green (ICG) [40]. In addition, they were shown to clear ammonia/produce urea [30,34,35], secrete albumin and/or uptake low density lipoprotein (LDL) [32,35,39].…”

Section: Plasticity: Mscs-derived Hepatocyte-like Cellsmentioning

confidence: 99%

See 1 more Smart Citation

Mesenchymal Stem/Stromal Cells in Liver Fibrosis: Recent Findings, Old/New Caveats and Future Perspectives

Fiore

Mazzolini

Aquino

2015

Stem Cell Rev and Rep

View full text Add to dashboard Cite

Mesenchymal stem/stromal cells (MSCs) are progenitors which share plastic-adherence capacity and cell surface markers but have different properties according to their cell and tissue sources and to culture conditions applied. Many recent publications suggest that MSCs can differentiate into hepatic-like cells, which can be a consequence of either a positive selection of rare in vivo pluripotent cells or of the original plasticity of some cells contributing to MSC cultures. A possible role of MSCs in hereditary transmission of obesity and/or diabetes as well as properties of MSCs regarding immunomodulation, cell fusion and exosome release capacities are discussed according to recent literature. Limitations in methods used to track MSCs in vivo especially in the context of liver cirrhosis are addressed as well as strategies explored to enhance their migratory, survival and proliferation properties, which are known to be relevant for their future clinical use. Current knowledge regarding mechanisms involved in liver cirrhosis amelioration mediated by naïve and genetically modified MSCs as well as the effects of applying preconditioning and combined strategies to improve their therapeutic effects are evaluated. Finally, first reports of GMP guidelines and biosafety issues in MSCs applications are discussed.

show abstract

Section: Plasticity: Mscs-derived Hepatocyte-like Cellsmentioning

confidence: 99%

Section: Plasticity: Mscs-derived Hepatocyte-like Cellsmentioning

confidence: 99%

Mesenchymal Stem/Stromal Cells in Liver Fibrosis: Recent Findings, Old/New Caveats and Future Perspectives

Fiore

Mazzolini

Aquino

2015

Stem Cell Rev and Rep

View full text Add to dashboard Cite

show abstract

“…In addition to fetal and adult hepatocytes, stem cells are considered for cell transplantation. PMSC can be helpful since their potential capacity to differentiate to hepatic-like cells and form functional three-dimensional structures have been reported [80].…”

Section: Use Of Placental Mesenchymal Stem/stromal Cells In Liver Dismentioning

confidence: 99%

Human Placenta-Derived Mesenchymal Stromal Cells: A Review from Basic Research to Clinical Applications

Torre¹,

Pérez-Lorenzo²,

Flores³

2019

Stromal Cells - Structure, Function, and Therapeutic Implications

Self Cite

View full text Add to dashboard Cite

Placenta-derived mesenchymal stem/stromal cells (PMSC) present several aspects that make them more attractive as cellular therapy than their counterparts from other tissues, such as MSC from bone marrow or adipose tissue in regenerative medicine. Placenta-derived MSC have been used to treat a variety of disorders, such as, cancer, liver and cardiac diseases, ulcers, bone repair, and neurological diseases. Placenta-derived MSC are relatively new types of MSC with specific immunomodulatory properties and whose mechanisms are still unknown. Placenta-derived MSC secrete some soluble factors that seem to be responsible for their therapeutic effects, i.e., they have paracrine effects. On the other hand, Placentaderived MSC can also serve as cellular vehicles and/or delivery systems for medications due to their migration capacity and their tropism for injury sites. Nanotechnology is an important field, which has undergone rapid development in recent years for the treatment of injured organs. Due to the special characteristics of placenta-derived MSC, the combination of these cells with nanotechnology will be a significant and highly promising field that will provide significant contributions in the regenerative medicine field in the near future.

show abstract

“…Placental tissues, both fetal (amniotic fluid, Wharton's jelly, amniotic membrane, chorionic villi) and maternal (decidua) represent an important source of MSCs with some advantages including the isolation of large number of cells in a non invasive way [32,33] . In addition, like [32][33][34][35] . An important issue in using MSCs is their safety.…”

Section: Mesenchymal Stem Cell Transplantationmentioning

confidence: 99%

“…In addition, like Flores AI et al . Stem cell in inflammatory bowel disease bone marrow MSCs, placenta-derived MSCs are nonimmunogenic and immunomodulatory stem cells with high expansion and differentiation capacity [32][33][34][35] . An important issue in using MSCs is their safety.…”

Section: Mesenchymal Stem Cell Transplantationmentioning

confidence: 99%

Stem cell therapy in inflammatory bowel disease: A promising therapeutic strategy?

Flores¹

2015

WJSC

View full text Add to dashboard Cite

Inflammatory bowel diseases are inflammatory, chronic and progressive diseases of the intestinal tract for which no curative treatment is available. Research in other fields with stem cells of different sources and with immunoregulatory cells (regulatory T-lymphocytes and dendritic T-cells) opens up new expectations for their use in these diseases. The goal for stem cell-based therapy is to provide a permanent cure. To achieve this, it will be necessary to obtain a cellular product, original or genetically modified, that has a high migration capacity and homes into the intestine, has high survival after transplantation, regulates the immune reaction while not being visible to the patient's immune system, and repairs the injured tissue. Core tip: Inflammatory bowel diseases are inflammatory, chronic and progressive diseases of the intestinal tract. A limited experience is available with hematopoietic and mesenchymal stem cell transplantation for the treatment of these conditions. Research is ongoing with other cell lines which have been used in conditions alike to inflammatory bowel disease and which will possibly have a therapeutic role in this condition. INTRODUCTIONInflammatory bowel disease (IBD) mainly consists of two clinical conditions, Crohn's disease (CD) and ulcerative colitis (UC). It is mainly characterized by chronic, destructive inflammation of the gastrointestinal tract for which no curative treatment is currently available.Its etiology is unknown, but it is accepted that it could be the result of loss of tolerance to intraluminal bowel antigens [1] . Genetic, environmental, and microbiological factors are involved in its development, Stem cell therapy in inflammatory bowel disease: A promising therapeutic strategy?Ana I Flores, Gonzalo J Gómez-Gómez, Ángeles Masedo-González, M Pilar Martínez-Montiel together with morphological and functional changes in the intestinal barrier associated to an impaired immune response [2] . Early data supporting genetic involvement in the pathogenesis of IBD come from familial clinical studies showing a greater incidence in twins [3,4] , first-degree relatives [5,6] and given ethnic groups [7,8] . Genome-wide association scan studies have allowed for identification of more than 163 loci associated to IBD [9] , 73 genes associated to CD and 47 to UC [10] , and overlapping genes for both conditions have also been found [11] . Genetic factors would however account for less than 25% of cases [12] . The exception is represented by a monogenic disorder referred to as IBD-like diseases, which are associated with severe colitis in childhood and have at most three loci alternatives [13] . On the other hand the increase of the incidence of IBD suggests that environmental factors are more important than genetic factors in the development of IBD [14] . Since IBD etiology is currently unknown, current treatment is intended to control the inflammatory intestinal process, thus avoiding irreversible structural damage. However, current therapeutic results are di...

show abstract

Human decidua-derived mesenchymal stromal cells differentiate into hepatic-like cells and form functional three-dimensional structures

Cited by 22 publications

References 52 publications

Mesenchymal Stem/Stromal Cells in Liver Fibrosis: Recent Findings, Old/New Caveats and Future Perspectives

Mesenchymal Stem/Stromal Cells in Liver Fibrosis: Recent Findings, Old/New Caveats and Future Perspectives

Human Placenta-Derived Mesenchymal Stromal Cells: A Review from Basic Research to Clinical Applications

Stem cell therapy in inflammatory bowel disease: A promising therapeutic strategy?

Contact Info

Product

Resources

About